Market Analysis: Global Rosacea Treatment Market
Market Definition: Global Rosacea Treatment Market
Rosacea is a chronic, inflammatory skin condition that is characterized by redness on skin. The symptoms are most common at cheeks, nose and forehead. The blush of redness can also spread to other parts such as ears, chest and back. It could be triggered due to heat, caffeine or stress.
Rosacea is often underdiagnosed or misdiagnosed as acne, making it hard to find out the exact prevalence rate of the disease. This disease is more prevalent in fair skin people. An estimated of 14 million people in the America suffers from rosacea.
Get More Insights About Global Rosacea Treatment Market, Request Sample @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-rosacea-treatment-market
Increasing government initiatives and investments in the treatment market will contribute in the market growth
Increasing research and development of advanced formulations for treatment of different types of rosacea and acne are expected to drive the market growth
Increasing prevalence rate of the disease acts as driver of market growth
Growing awareness about rosacea and its available therapeutics will increase the market size
Multiple patent expiries bring a significant number of generic products that hampers the growth of market
Off-label usage of medicines for rosacea can also restrict the market growth
Rosacea is often underdiagnosed or misdiagnosed as acne hampers the market growth
Know more about this report https://www.databridgemarketresearch.com/reports/global-rosacea-treatment-market
Segmentation: Global Rosacea Treatment Market
By Drugs Class
By Route of Administration
By End Users
By Distribution Channels
Rest of South America
Rest of Europe
Rest of Asia Pacific
Middle East & Africa
Rest of Middle East & Africa
Key Developments in the Market:
In August 2019, Foamix Pharmaceuticals Ltd. submitted a New Drug Application (NDA) to the U. S. FDA for FMX103 (minocycline) for the treatment of moderate-to-severe papulopustular rosacea. This application is based on the positive topline results of phase III clinical trials of FMX103. This drug candidate will be an efficacious treatment with a well-tolerated profile and will be present in a convenient topical foam formulation
In January 2017, ALLERGAN received the U. S. FDA approval for RHOFADE topical cream used for treatment of adults with persistent facial erythema associated with rosacea. The approval was based on two clinical trials which met the primary efficacy endpoint. This approval will provide ALLERGAN all the right for production and commercialization of this novel formulation.
Key Market Players:
Few of the major competitors currently working in the global rosacea treatment market are Foamix Pharmaceuticals Ltd., ALLERGAN, Bausch Health, Sol-Gel Technologies Ltd., Bayer AG, Nestlé, PRUGEN, Merck & Co., Inc., AbbVie Inc., Unilever, Croda International Plc, Colorescience, Inc., Perrigo Company plc, Aclaris Therapeutics, Inc., Lupin Pharmaceuticals, Inc., Supernus Pharmaceuticals, Inc, Dr. Reddy’s Laboratories Ltd., Mylan N.V. among others.
Demand Side: Doctors, Surgeons, Medical Consultants, Nurses, Hospital Buyers, Group Purchasing Organizations, Associations, Insurers, Medical Payers, Healthcare Authorities, Universities, Technological Writers, Scientists, Promoters, and Investors among others.
Supply Side: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, and Regulatory Affairs Managers among others.
Request for Detailed TOC @ https://www.databridgemarketresearch.com/toc/?dbmr=global-rosacea-treatment-market
Browse Trending Related Reports @
About Data Bridge Market Research: